ORIGINAL ARTICLE: Bivalirudin during Primary PCI in Acute Myocardial Infarction
Mercredi 21 Mai 2008 - 06:55 - 7 mois, 3 semaines depuis
-
Presse spécialisée
-
New England Journal of Medicin
Bivalirudin is a direct thrombin inhibitor. As compared with a combination of heparin and a glycoprotein IIb/IIIa inhibitor, bivalirudin use resulted in less bleeding and lower 30-day mortality among patients undergoing PCI for acute myocardial infarction. However, bivalirudin was associated with a higher rate of acute stent thrombosis within 24 hours.